# Targeting the Tumor Microenvironment in R/M SCCHN

> **NCT03844763** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 71 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** CTX
- **RADIATION:** RT

## Key facts

- **NCT ID:** NCT03844763
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-07
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03844763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03844763, "Targeting the Tumor Microenvironment in R/M SCCHN". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03844763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*